Press Releases

Details on the timetable of the simplified tender offer on North Atlantic Energies shares Leave a reply Paris, Jan. 30, 2026 (GLOBE NEWSWIRE) — NORTH ATLANTIC ENERGIES Details on the timetable of the simplified tender offer on North Atlantic Energies shares Paris, FRANCE – January 30, 2026 – North Atlantic France SAS (“North Atlantic France”) refers to its acquisition from ExxonMobil France Holding SAS (“ExxonMobil”) of ExxonMobil’s entire stake in North Atlantic Energies (formerly, Esso Société Anonyme Française SA) (“North Atlantic Energies”), representing 82.89% of North Atlantic Energies’ share capital and voting rights. In accordance with French securities law, North Atlantic France announced on November 28, 2025 that it would file a simplified tender offer (the “Offer”) for the remaining North Atlantic Energies shares not already held by North Atlantic France, at a price of €28.93 per share, as well as its intention to implement a squeeze-out procedure if the conditions required are met. It is reminded that the board of directors of North Atlantic Energies has appointed Ledouble SAS, represented by Ms. Agnès Piniot and Mr. Romain Delafont, as an independent expert to issue a fairness opinion on the financial terms of the Offer. North Atlantic France indicates that it will file the Offer with the Autorité des marchés financiers (the “AMF”) once the independent expert’s work has been finalised, after the publication of the 2025 annual results. North Atlantic Energies indicates that this publication is scheduled for March 26, 2026. The filing is therefore expected to take place during the second quarter of 2026. The offer documentation will be submitted to the AMF for review, and the Offer will only open once the AMF has issued its compliance decision. MEDIA CONTACTS France: Brunswick Group – [email protected] Hugues Boëton: +33 6 79 99 27 15 Paul Priam: +33 6 84 39 09 89 Canada:

Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis Leave a reply Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential. Rocatinlimab’s novel approach as an investigational T-cell rebalancing therapy directly targeting the OX40 receptor expressed on pathogenic T-cells shows potential to deliver long-term disease control in patients with moderate-to-severe atopic dermatitis (msAD). Regulatory submission is planned in the first half of 2026. TOKYO and PRINCETON, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) — Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the termination of the current rocatinlimab development and commercialization collaboration with Amgen. Kyowa Kirin will regain control of the global rocatinlimab program, including regulatory filings and future commercialization. This business decision is the result of a strategic portfolio prioritization by Amgen. The companies are initiating a smooth and orderly transition of the program, with a focus on ensuring continuity for participants currently enrolled in clinical trial programs. Amgen, who has partnered with Kyowa Kirin on numerous investigational therapies over 41 years, will continue to manufacture rocatinlimab. “Kyowa Kirin is confident in the potential of rocatinlimab to address critical unmet needs for patients with moderate-to-severe atopic dermatitis who are looking for new, long-lasting options that may address the chronic nature of unpredictable flares,” said Abdul Mullick, Ph.D., President and Chief Operating Officer of Kyowa Kirin. “Rocatinlimab’s science and its highly differentiated mechanism of action targeting the OX40 receptor make it a potentially unique treatment option. We are excited to build on the strong clinical program we have established and apply our extensive clinical and commercial expertise to help make patients smile with what is a key strategic priority for Kyowa Kirin going